| Identification | Back Directory | [Name]
Glycine, N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-, 1,1-dimethylethyl ester | [CAS]
2093386-23-1 | [Synonyms]
Thalidomide-NH-CH2-COO(t-Bu)
tert-Butyl (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycinate
Glycine, N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-, 1,1-dimethylethyl ester | [Molecular Formula]
C19H21N3O6 | [MOL File]
2093386-23-1.mol | [Molecular Weight]
387.39 |
| Hazard Information | Back Directory | [Uses]
Thalidomide-NH-CH2-COO (t-Bu) is a ligand for E3 ubiquitin ligase PROTAC BET Degrader-1 (HY-103633)[1]. | [IC 50]
Cereblon | [References]
[1] Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. DOI:10.1021/acs.jmedchem.6b01816 |
|
| Company Name: |
Pharmalego
|
| Tel: |
18321033991 18321033991 |
| Website: |
cn.pharmalego.com/ |
|